Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2

Autor:	Brandi N. Williamson, Lizzette Pérez-Pérez, Benjamin Schwarz, Friederike Feldmann, Myndi G. Holbrook, Manmeet Singh, Diane S. Lye, Darius Babusis, Raju Subramanian, Elaine Haddock, Atsushi Okumura, Patrick W. Hanley, Jamie Lovaglio, Catharine M. Bosio, Danielle P. Porter, Tomas Cihlar, Richard L. Mackman, Greg Saturday, Emmie de Wit
Rok vydání:	2022
Předmět:	Male Pharmacology Alanine SARS-CoV-2 COVID-19 Viral Load Administration Cutaneous Virus Replication Antiviral Agents Macaca mulatta Adenosine Monophosphate Article COVID-19 Drug Treatment Disease Models Animal Virology Animals Female Animal model Antiviral Lung Diseases Interstitial Lung
Zdroj:	Antiviral Research
ISSN:	0166-3542
Popis:	The utility of remdesivir treatment in COVID-19 patients is currently limited by the necessity to administer this antiviral intravenously, which has generally limited its use to hospitalized patients. Here, we tested a novel, subcutaneous formulation of remdesivir in the rhesus macaque model of SARS-CoV-2 infection that was previously used to establish the efficacy of remdesivir against this virus in vivo. Compared to vehicle-treated animals, macaques treated with subcutaneous remdesivir from 12 h through 6 days post inoculation showed reduced signs of respiratory disease, a reduction of virus replication in the lower respiratory tract, and an absence of interstitial pneumonia. Thus, early subcutaneous administration of remdesivir can protect from lower respiratory tract disease caused by SARS-CoV-2.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d0568d8d54147371bcfcba2b9ff1fca https://doi.org/10.1016/j.antiviral.2022.105246 Zobrazit plný text záznamu Full Text from ScienceDirect